1. US Breast Cancer Drug Market Analysis

  1.1 US Breast Cancer Market Overview

  1.2 Current Market Scenario

2. Approved Breast Cancer Drugs by Class

  2.1 Chemotherapeutic Drugs

  2.2 Hormonal Therapy

  2.3 Immunotherapeutic Drugs

    2.3.1 Targeted Antibodies (ADC/Monclonal /Trispecific)

    2.3.2 Immune Checkpoint Inhibitors

  2.4 Kinase Inhibitors

3. New Emerging Therapies in Breast Cancer

  3.1 Targeted Endocrine Therapy

  3.2 Oral Selective Estrogen Receptor Degrader (SERD)

  3.3 Immunotherapeutics through Cancer Vaccines

  3.4 Tri-Specific NK Cell Engagers (TriKE)

  3.5 Adoptive T Cell Therapy

4. US Breast Cancer Drug: Generic and Biosimilar Landscape

  4.1 Current Scenario and Price Differential

  4.2 Reimbursement Policy

5. US - Breast Cancer Clinical Trials Overview

  5.1 By Drug Class

  5.2 By Formulation

  5.3 By Organization

  5.4 By Patient Segment

  5.5 By Phase

  5.6 By Target

6. US - Breast Cancer Clinical Trials By Company, Indication and Phase

  6.1 Research

  6.2 Preclinical

  6.3 Clinical

  6.4 Phase-0

  6.5 Phase-I

  6.6 Phase-I/II

  6.7 Phase-II

  6.8 Phase-II/III

  6.9 Phase-III

  6.10 Preregistration

 6.11 Registered

7. US - Marketed Breast Cancer Drugs Clinical Insight

8. CDK 4/6 Inhibitors for Breast Cancer - US Market Availability, Dosage, Patent and Price Insight

  8.1 Ribociclib (Kisqali)

  8.2 Abemaciclib (Verzenio)

  8.3 Palbociclib (Ibrance)

9. EGFR Inhibitors for Breast Cancer - US Market Availability, Dosage, Patent and Price Insight

  9.1 Nertinib (Nerlynx)

  9.2 Lapatinib (Tykerb)

10. Mitotic Inhibitors for Breast Cancer - US Market Availability, Dosage, Patent and Price Insight

  10.1 Ixabepilone (Ixempra)

  10.2 Eribulin (Halaven)

  10.3 Paclitaxel-Protein Bound (Abraxane)

  10.4 Paclitaxel (Taxol)

  10.5 Docetaxel (Taxotere)

11. Aromatase Inhibitors for Breast Cancer - US Market Availability, Dosage, Patent and Price Insight

  11.1 Anastrazole (Arimidex)

  11.2 Letrozole (Femara)

  11.3 Exemestane (Aromasin)

12. Hormonal Drugs for Breast Cancer - US Market Availability, Dosage, Patent and Price Insight

  12.1 Raloxifene (Evista)

  12.2 Tamoxifen (Soltamax)

  12.3 Testosterone Cypionate (Depo-Testosterone)

  12.4 Fluoxymesterone

  12.5 Fareston (Toremifene)

13. Antimetabolite Drugs for Breast Cancer - US Market Availability, Dosage, Patent and Price Insight

  13.1 Gemcitabine (Gemzar)

  13.2 Capecitabine (Xeloda)

  13.3 Flourouracil

  13.4 Methotrexate

14. PARP Inhibitors for Breast Cancer - US Market Availability, Dosage, Patent and Price Insight

  14.1 Olaparib (Lynparza)

  14.2 Talazoparib (Telzenna)

15. Immunotherapy Drugs for Breast Cancer - US Market Availability, Dosage, Patent and Price Insight

  15.1 Herceptin (Trastuzumab)

  15.2 Avastin (Bevacizumab)

  15.3 Perjeta (Pertuzumab)

  15.4 Kadcyla (Ado-Trastuzumab Emtansine)

  15.5 Tecentriq (Atizolizumab)

  15.6 Keytruda (Pembrolizumab)

  15.7 Enhertu (Fam-Trastuzumab Deruxtecan)

  15.8 Phesgo (Hyaluronidase / Pertuzumab / Trastuzumab)

  15.9 Herceptine Hylecta (Hyaluronidase / Trastuzumab)

  15.10 Trodelvy (Sacituzumab Govitecan)

16. SERD for Breast Cancer - US Market Availability, Dosage, Patent and Price Insight

  16.1 Fulvestrant (Faslodex) - Approval and Patent Dispute

  16.2 Pricing and Dosage Analysis

  16.3 Sales Analysis

17. Alkylating Agents for Breast Cancer - US Market Availability, Dosage, Patent and Price Insight

  17.1 Cyclophosphamide

  17.2 Thiotepa

18. Other Breast Cancer Drugs - US Market Availability, Dosage, Patent and Price Insight

  18.1 Tucatinib

  18.2 Doxorubicin

  18.3 Everolimus

  18.4 Alpelisib (Piqray)

19. US Breast Cancer Market Insights for Ongoing Research Work and Development

  19.1 Single Dose Radiotherapy Beneficial Over Other Conventional Breast Cancer

   Treatment Options

  19.2 Targeted Therapy to Emerge as Novel and Promising Opportunity for Breast

   Cancer Treatment

  19.3 UCLA Researchers Define the Lack of Predictive Biomarkers in Breast Cancer

   Treatment

  19.4 Development of Novel Model for Breast Cancer Patients by UCSF Researchers

  19.5 Artificial Intelligence Applications Aids in the Development of Breast Cancer

  Treatment

  19.6 More Promising Survival Rate of the Breast Cancer Patients due to Surgery

  Applications

  19.7 Immunotherapy to Converge the Entire US Breast Cancer Market towards its

  Applications

  19.8 Estrogen Positive Breast Cancer Patients to Receive Potential Drug

   Combination for Treatment

  19.9 TNBC to Receive Special Attention for Novel Therapeutic Treatment Option

  19.10 Rockefeller University Researchers to Introduce Telomere into Breast Cancer

  Treatment

  19.11 Veru Oncology Pharmaceuticals Expansion of Clinical Pipeline for Breast

  Cancer

  19.12 MIT Researchers to Revolutionize Breast Cancer Screening Methodologies by

   Artificial Intelligence Applications

  19.13 Researchers to Explore More Hidden Parameters for Breast Cancer Tumors

  19.14 Environmental Factors Exposure Study on Breast Cancer Development

  19.15 Targeted Therapy to Improve Breast Cancer Treatment in Mice Model

20. Research and Collaborations Advancing the US Breast Cancer Market at a Splendid Rata

  20.1 Celcuity, Massachusetts General Hospital and Puma Biotechnology to Enter into

   Collaboration for Advancing US Breast Cancer Market

  20.2 US Based Pharmaceutical Company Pfizer to Collaborate with Japanese

  Pharmaceuticals to Expand Breast Cancer Market

  20.3 MacroGenics and EVERSANA to Collaborate for Launch and Commercialization of

  Margetuximab Drug

  20.4 New York Based Ibi and Atos Partners to Build Data for Breast Cancer Studies

  20.5 NCCN and Pfizer to Collaborate for the Development of Metastatic Breast

  Cancer Market

  20.6 Alphamab Oncology and Pfizer to Work Together on Ibrance Drug for HER2

  Positive Breast Cancer Patients

  20.7 Pfizer and Zymeworks to collaborate for Evaluating ZW25 Combination Therapy

  in Breast Cancer Patients

  20.8 Pfizer and Flatiron Health to Expand Market for Breast Cancer Medicine

  Development

21. US Breast Cancer Market Dynamics

    21.1 Market Favorable Parameters

    21.2 Market Challenges

22. US Breast Cancer Market Future Prospects

23. Competitive Landscape

    23.1 Agilent Technologies

    23.2 AstraZeneca

    23.3 Bayer HealthCare Pharmaceuticals

    23.4 Bristol-Myers Squibb

    23.5 Eisai Co Ltd

    23.6 Eli Lilly

    23.7 Novartis

    23.8 Onyx Pharmaceuticals

    23.9 Orion

    23.10 Perrigo

    23.11 Pfizer

    23.12 Roche

Figure 1-1: US - Breast Cancer New Cases and Deaths, 2020

Figure 1-2: US - Breast Cancer Cases by Gender, 2020

Figure 1-3: US - Breast Cancer Drug Market Opportunity (US$ Billion), 2020 - 2026

Figure 1-4: Global - Herceptin and Perjata Annual Sales by Region (US$ Million), 2019

Figure 1-5: US - Herceptin Annual Sales (US$ Million), 2018 and 2019

Figure 2-1: Mechanism of Action of Various Chemotherapeutic Drugs

Figure 2-2: Various Targets in Hormonal Therapy

Figure 2-3: Mode of Action of Immune Checkpoint Inhibitors

Figure 2-4: Mechanism of CDK4/6 Inhibitors

Figure 2-5: Potential targets in the PI3K/AKT/mTOR pathway

Figure 3-1: SERD in Clinical Development for ER+ve/HER2-ve Breast Cancer

Figure 4-1: Herceptin - Cost of Branded and Generic Drugs (US$)

Figure 4-2: Adriamycin – Cost of Branded and Generic Drugs (US$ )

Figure 4-3: US - Breast Cancer Drug Annual sales (US$ Million), 2019

Figure 4-4: Kanjinti – Total Treatment Cost and Reimbursement Cost (US$ )

Figure 4-5: Kanjinti- In Pocket Cost and Out Pocket Cost (in %)

Figure 5-1: US - Number of Beast Cancer Drugs in Clinical Trials by Drug Class,  2021 till 2026

Figure 5-2: US - Number of Beast Cancer Drugs in Clinical Trials by Formulation,  2021 till 2026

Figure 5-3: US - Number of Beast Cancer Drugs in Clinical Trials by Organization,  2021 till 2026

Figure 5-4: US - Number of Beast Cancer Drugs in Clinical Trials by Patient Segment,  2021 till 2026

Figure 5-5: US - Number of Beast Cancer Drugs in Clinical Trials by Phase,  2021 till 2026

Figure 5-6: US - Number of Beast Cancer Drugs in Clinical Trials by Target,  2021 till 2026

Figure 8-1: Kisqali – FDA Approval Year by Indication

Figure 8-2: Kisqali - Patent Issue and Expiration Year

Figure 8-3: Kisqali – Price for Supply of 21, 42 and 63 Tablets of 200mg (US$), January’2021

Figure 8-4: Kisqali – Duration of Treatment Cycle by Phase

Figure 8-5: Verzenio – Patent Issue and expiration Year

Figure 8-6: Verzenio – Price for a Supply of 14 Tablets and Price per unit Tablet (US$), January’2021

Figure 8-7: Verzenio – Dose by Type of Therapy (mg/Twice daily), January’2021

Figure 8-8: Verzenio Monotherapy – Initial and Reduced Dose (mg/Twice daily), January’2021

Figure 8-9: Verzenio Combinational – Initial and Reduced Dose (mg/Twice daily), January’2021

Figure 8-10: US - Verzenio Annual Sales Value (US$ Million), 2017 - 2019

Figure 8-11: US - Verzenio Quarterly Sales Value (US$ Million), 2019

Figure 8-12: US - Verzenio Quarterly Sales Value (US$ Million), Q1 – Q3, 2020

Figure 8-13: Ibrance – FDA Approval by Indication

Figure 8-14: Ibrance – Patent Issue and Expiration Year

Figure 8-15: Ibrance – Price for 21 Capsule and Price per unit Capsule (US$), January’2021

Figure 8-16: Ibrance – Recommended and Reduced Dose (mg/day)

Figure 8-17: US - Ibrance Annual Sales Value (US$ Million), 2017 - 2019

Figure 8-18: Ibrance - Annual Sales Value by Region (US$ Million), 2019

Figure 8-19: Ibrance – Annual Sales Value by Region (%), 2019

Figure 8-20: US - Ibrance Quarterly Sales value (US$ Million), 2018 and 2019

Figure 8-21: US - Ibrance Quarterly Sales value (US$ Million), Q1 – Q3, 2020

Figure 9-1: Nertininb – FDA Approval and Patent Expiration Year

Figure 9-2: Nerlynx – Price for 180 Tablet Supply and Price per unit Tablet of 40mg Tablet (US$), January’2021

Figure 9-3: Tykerb – Patent Issue and Expiration Year

Figure 9-4: Tykerb – Price for 150 Tablets and Price per Unit Tablet of 150mg (US$), January’2021

Figure 9-5: Tykerb – Recommended Dose by Indication (mg/day)

Figure 10-1: Ixempra – FDA Approval and Patent Expiration Year

Figure 10-2: Ixempra – Price for 15m and 45mg Powder for Injection (US$), January’2021

Figure 10-3: Ixempra – Average and Maximum Cost of Single Treatment Cycle (US$), January’2021

Figure 10-4: Halaven – FDA Approval Year by Indication

Figure 10-5: Halaven – Patent Issue and Expiration Year

Figure 10-6: Halaven – Price for 2ml Supply and Price per ml of Intravenous Solution (US$), January’2021

Figure 10-7: Halaven – Recommended and Reduced Dose (mg/m2twice daily), January’2021

Figure 10-8: Abraxane – FDA Approval Year by Indication

Figure 10-9: Abraxane – US and Europe Patent Expiration Year

Figure 10-10: Abraxane – Recommended Single Dose by Indication (mg/m2)

Figure 10-11: Abraxane – Duration of Single Treatment Cycle (Week)

Figure 10-12:  Abraxane – Cost of Single Treatment Cycle and Annual Treatment Cost of Breast Cancer (US$), January’2021

Figure 10-13:  Abraxane – Cost of Single Treatment Cycle and Annual Treatment Cost of NSCLC (US$), January’2021

Figure 10-14:  Abraxane – Cost of Single Treatment Cycle and Annual Treatment Cost of Pancreatic Cancer (US$), January’2021

Figure 10-15: US - Abraxane Annual Sales Value (US$ Million), 2017 - 2019

Figure 10-16: Abraxane – US v/s Rest of World Annual Sales Value (US$ Million), 2019

Figure 10-17: Abraxane – US v/s Rest of World Annual Sales Value (US$ Million), 2019

Figure 10-18: Abraxane – US Quarterly Sales Value (US$ Million), 2019

Figure 10-19: US – Abraxane Quarterly Sales Value (US$ Million), Q1-Q3, 2020

Figure 10-20: Taxol - FDA Approval and First Generic Approval Year

Figure 10-21: Paclitaxel – Average Price for Various Supplies of 6mg/ml Intravenous Solution (US$), January’2021

Figure 10-22: Paclitaxel – Recommended Dose by Cancer Type (mg/m2/3weeks)

Figure 10-23: Taxotere – FDA Approval year by Strength

Figure 10-24: Taxotere – First Generic Approval year by Strength

Figure 10-25: Docetaxel – FDA Approval year by Companies

Figure 10-26: Taxotere – Price for 4ml Supply and Price per ml of 20mg/ml Intravenous Solution (US$, January’2021

Figure 10-27: Docetaxel – Average Price for 2ml, 8ml and 16ml Supply 10mg/ml Intravenous Solution (US$), January’2021

Figure 10-28: Docetaxel – Average Price for 1ml, 4ml, 8ml and 10ml Supply 20mg/ml Intravenous Solution (US$, January’2021

Figure 10-29: Docetaxel – Minimum and Maximum Dose for breast Cancer Management (mg/m2/3 weeks)

Figure 11-1: Arimidex – FDA Approval and Patent Expiration Year

Figure 11-2: Arimidex – Price for 30 Tablets Supply and Price per unit Tablet (US$), January’2021

Figure 11-3: Anastrazole – Average Price for 30 Tablets Supply and Price per unit Tablet (US$), January’2021

Figure 11-4: Fareston – FDA Approval and First Generic Approval Year

Figure 11-5: Femara – Price for 30 Tablets and price per unit Tablet of 2.5 mg (US$), January’2021

Figure 11-6: Generic Toremifene – Price for Various Tablet Supplies of 2.5mg (US$), January’2021

Figure 11-7: Aromasin – FDA Approval and First Generic Approval Year

Figure 11-8: Aromasin – Price for 30 Tablet Supply and Price per unit Tablet (US$), January’2021

Figure 11-9: Generic Exemestane – Price for 30 Tablet Supply and Price per unit Tablet (US$), January’2021

Figure 12-1: Raloxifdene – FDA Approval and First Generic Approval Year

Figure 12-2: Evista – Price for 30 Tablets Supply and Price per Unit tablet (US$), January’2021

Figure 12-3: Evista – Price for 100 Tablets Supply and Price per Unit tablet (US$), January’2021

Figure 12-4: Generic Raloxifene – Price for Various Supplies of 60mg Tablet (US$), January’2021

Figure 12-5: Soltamax – Price for 150 ml Supply and Price per unit ml of Oral Solution (US$), January’2021

Figure 12-6: Soltamax – Minimum and Maximum Dose for Metastatic Breast Cancer Treatment (mg/day)

Figure 12-7: Soltamax – Minimum and Maximum Duration for Breast Cancer Treatment (Years)

Figure 12-8: Depo-testosterone – Price for 10ml and Price per ml of 100mg/ml Intramuscular Solution (US$), January’2021

Figure 12-9: Depo-testosterone – Price for 10ml and 1 ml Supplies of 200mg/ml Intramuscular Solution (US$), January’2021

Figure 12-10: Fluoxymesterone – Price for the Supply of 100 Tablets and Price per Unit Tablet of 10mg (US$), January’2021

Figure 12-11: Fluoxymesterone – Minimum and Maximum Daily Dose (mg)

Figure 12-12: Fareston – FDA Approval and First Generic Approval Year

Figure 12-13: Fareston – Price for 30 Tablets and Price per Unit of 60mg Tablet (US$), January’2021

Figure 12-14: Toremifene – Price for 30 Tablets and Price per Unit of 60mg Tablet (US$), January’2021

Figure 13-1: Gemzar – FDA Approval and First Generic Approval Year

Figure 13-2: Gemzar – Price for the Supply of 1 Gram and 200mg Powder for Injection (US$), January’2021

Figure 13-3: Generic Gemcitabine – Average Price for Various Supplies of Intravenous Powder for Injection (US$), January’2021

Figure 13-4: Generic Gemcitabine – Average Price for Various Supplies of 38mg/ml Intravenous Solution for Injection (US$), January’2021

Figure 13-5: Generic Gemcitabine – Average Price for Various Supplies of 100mg/ml Intravenous Solution for Injection (US$), January’2021

Figure 13-6: Gemzar – Duration of Initial and Subsequent Treatment Cycles (Days), January’2021

Figure 13-7: Gemzar – Cost of Single Treatment Cycle and Cost of Single Administration (US$), January’2021

Figure 13-8: Xeloda – FDA Approval Year and First Generic Approval Year

Figure 13-9: Capecitabine – Price for 60 Tablet Supply and Price per unit of 150mg Branded and Generic tablet (US$), January’2021

Figure 13-10: Xeloda – Price for 120 Tablet Supply and Price per unit of 500mg tablet (US$), January’2021

Figure 13-11: Capecitabine – Price for 120 Tablet Supply and Price per unit of 500mg tablet (US$), January’2021

Figure 13-12: Capecitabine – Duration of Single Treatment Cycle and Full Treatment (Weeks)

Figure 13-13: Flourouracil – Price for various Supplies of intravenous Solution for Injection (US$), January’2021

Figure 13-14: Fluorouracil – Recommended Minimum and Maximum Dose as Single Agent (mg/m2/ Twice a Cycle), January’2021

Figure 13-15: Fluorouracil – Duration of Single Treatment Cycle and Full Treatment (Weeks), January’2021

Figure 13-16: Methotrexate – Average Price of 10 ml Supply and Price per ml of 25mg/ml Intravenous Solution (US$), January’2021

Figure 13-17: Methotrexate – Average Price of Different Supplies of Oral Tablet (US$), January’2021

Figure 13-18: Trexall – Price for 30 Tablet Supplies of Various Dose Regimens (US$), January’2021

Figure 14-1: Lynparza – FDA Approval Year by Indication

Figure 14-2: Lynparza - Number of Patent Issued by Assignee Name

Figure 14-3: Lynparza – Patent Expiration Year by Assignee

Figure 14-4: Lynparza – Price for 60 and 120 Tablet Supply and Price per Unit Tablet (US$), January’2021

Figure 14-5: Lynparza – Recommended Dose and Dose after Reduction (mg/day)

Figure 14-6: US - Lynparza Annual Sales Value (US$ Million), 2017 - 2019

Figure 14-7: Lynparza - Annual Sales Value by Region (US$ Million), 2019

Figure 14-8: Lynparza – Annual Sales Value by Region (%), 2019

Figure 14-9: US - Lynparza Quarterly Sales Value (US$ Million), 2019

Figure 14-10: US - Lynparza Quarterly Sales Value (US$ Million), Q1-Q3, 2020

Figure 14-11: Telzenna – Medivation’s Patent Issue and Expiration Year

Figure 14-12: Telzenna – BioMarin’s Patent Issue and Expiration Year

Figure 14-13: Telzenna – Price for 30 Capsule Supply of and Price per Unit Capsule of 0.25mg (US$), January’2021

Figure 14-14: Telzenna – Price for 30 Capsule Supply of and Price per Unit Capsule of 1mg (US$), January’2021

Figure 14-15: Telzenna – Recommended Initial and Reduced Dose (mg/Day), January’2021

Figure 15-1: Herceptin – Approval Year by Cancer Type

Figure 15-2: Herceptin – Price for a Supply of 10 and Price for Single 150mg Powder for Injection (US$), January’2021

Figure 15-3: Herceptin – Initial and Maintenance Dose for Breast Cancer Treatment (mg/kg), January’2021

Figure 15-4: Herceptin – Cost of Initial Dose, Maintenance Dose and Annual Treatment Cost of Breast Cancer (US$), January’2021

Figure 15-5: Herceptin – Initial and Maintenance Dose for Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (mg/kg), January’2021

Figure 15-6: Herceptin – Cost of Initial Dose, Maintenance Dose and Annual Treatment Cost of Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (US$), January’2021

Figure 15-7: US - Herceptin Annual Sales Value (US$/CHF Million), 2017 - 2019

Figure 15-8: US - Herceptin Quarterly Sales Value (US$/CHF Million), 2019

Figure 15-9: US - Herceptin Quarterly Sales Value (US$ Billion), Q1-Q3, 2020

Figure 15-10: Avastin – Price for a Supply of 10 and Price for Single 4ml Solution for Injection (US$), January’2021

Figure 15-11: Avastin – Price for a Supply of 10 and Price for Single 16ml Solution for Injection (US$), January’2021

Figure 15-12: Avastin’s Biosimilar - FDA Approval Year

Figure 15-13: Mvasi - Price for 4ml Supply and Price per ml of Intravenous Solution (US$), January’2021

Figure 15-14: Mvasi - Price for 16 ml Supply and Price per Unit of Intravenous Solution (US$), January’2021

Figure 15-15: Zirabev - Price for 4ml Supply and Price per unit of Intravenous Solution (US$), January’2021

Figure 15-16: Zirabev - Price for 16 ml Supply and Price per unit of Intravenous Solution (US$), January’2021

Figure 15-17: US - Avastin Annual Sales Value (US$/CHF Billion), 2017 - 2019

Figure 15-18: US - Avastin Quarterly Sales Value (US$ Billion), 2019

Figure 15-19: US - Avastin Quarterly Sales Value (US$ Million), Q1-Q3, 2020

Figure 15-20: Perjeta - Approval Year by Cancer Type

Figure 15-21: Perjeta – Patent Expiration Year by Region

Figure 15-22: Perjeta – Price for a Supply of 10 ml and Price per ml of Intravenous Solution (US$), January’2021

Figure 15-23: Perjeta – Initial and Maintenance Dose for Breast Cancer Treatment (mg/ 3 weeks), January’2021

Figure 15-24: Perjeta – Minimum and Maximum Treatment Cost for Breast Cancer (US$), January’2021

Figure 15-25: Perjeta – Minimum and Maximum Treatment Cost of Neoadjuvant Breast Cancer Treatment (US$), January’2021

Figure 15-26: US - Perjeta Annual Sales Value (US$/CHF Million), 2017 - 2019

Figure 15-27: US - Perjeta Quarterly Sales Value (US$ Billion), 2019

Figure 15-28: US - Perjeta Quarterly Sales Value (US$ Million), Q1-Q3, 2020

Figure 15-29: Kadcyla – FDA Approval Year for Late Stage and Early Stage HER2+ Breast Cancer

Figure 15-30; Kadcyla – Price for Single Unit of 100mg and 160mg Intravenous Powder for Injection (US$), January’2021

Figure 15-31: Kadcyla - Duration of Single Treatment Cycle and Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)

Figure 15-32: Kadcyla – Average Cost of Single Treatment Cycle and Full Treatment of Early Stage HER2 Breast Cancer in Human with Average Weight (US$), January’2021

Figure 15-33: Kadcyla – Recommended Dose After 1st and 2nd Dose Reduction (mg/m2)

Figure 15-34: US - Kadcyla Annual Sales Value (US$/CHF Million), 2017 - 2019

Figure 15-35: US - Kadcyla Quarterly Sales Value (US$ Billion), 2019

Figure 15-36: US - Kadcyla Quarterly Sales Value (US$ Million), Q1-Q3, 2020

Figure 15-37: Tecentriq - Price for 14ml Supply and Price per ml of 840mg/14ml Intravenous Injection (US$), January’2021

Figure 15-38: Tecentriq - Price for 20ml Supply and Price per ml of 1200mg/20ml Intravenous Injection (US$), January’2021

Figure 15-39: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 840mg/2 Week Dose (US$), January’2021

Figure 15-40: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1200mg/3 Week Dose (US$), January’2021

Figure 15-41: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1680mg/4 Week Dose (US$), January’2021

Figure 15-42: US - Tecentriq Annual Sales Value (US$/CHF Million), 2017 - 2019

Figure 15-43: US - Tecentriq Quarterly Sales Value (US$ Billion), 2019

Figure 15-44: US - Tecentriq Quarterly Sales Value (US$ Million), Q1-Q3, 2020

Figure 15-45: Keytruda – Patent Expiration Year by Region

Figure 15-46: Keytruda – Price for 4ml and 8ml Supply and Price per ml of Intravenous Injection (US$), January’2021

Figure 15-47: Keytruda – Duration of Single Treatment Cycle and Full Treatment of Melanoma and Other Cancers (Weeks), January’2021

Figure 15-48: Keytruda - Cost of Single and Full Treatment using Solution of Injection (US$), January’2021

Figure 15-49: US - Keytruda Annual Sales Value (US$ Billion), 2017 - 2019

Figure 15-50: US - Keytruda Quarterly Sales Value (US$ Million), 2018 and 2019

Figure 15-51: US - Keytruda Quarterly Sales Value (US$ Million), 2020

Figure 15-52: Enhertu – Cost of Single Supply and Single Treatment Cycle (US$), January’2021

Figure 15-53: Enhertu – Recommended Initial and Reduced Dose (mg/Kg/Cycle), January’2021

Figure 15-54: Phesgo – Price for various Supplies of Subcutaneous Solution for Injection (US$), January’2021

Figure 15 -55: Phesgo – Duration of Treatment by Type (Cycles), January’2021

Figure 15-56: Herceptin Hylecta – Price for 5ml and Price per ml of Subcutaneous Solution for Injection (US$), January’2021

Figure 15-57: Herceptin Hylecta – Duration of Single Treatment Cycle and Full Treatment (week), January’2021

Figure 15-58: Trodelvy – FDA Approval and Patent Expiration Year

Figure 15-59: Trodelvy – Average Cost of Single Treatment Cycle and Full Treatment, January’2021

Figure 16-1: Faslodex – FDA Approval Year by Type of Breast Cancer

Figure 16-2: Faslodex – FDA Approval Year and First Generic Approval Year

Figure 16-3: Faslodex - Patent Issue and Expiration Year

Figure 16-4: Faslodex – Price for 10 ml and Price per ml of Intramuscular Injection (US$), January’2021

Figure 16-5: Faslodex – Recommended and Reduced Dose (mg)

Figure 16-6: Faslodex – Number of Doses by Treatment Phase

Figure 16-7: Faslodex – Cost For First and Subsequent Treatment Cycle (US$), January’2021

Figure 16-8: Global - Faslodex Annual Sales Value (US$ Million), 2016 - 2019

Figure 16-9: Global - Faslodex Annual Sales Values (US$ Million), 2002 - 2015

Figure 16-10: Global - Faslodex Quarterly Sales Value (US$ Million), 2018 and 2019

Figure 16-11: US - Faslodex Annual Sales Value (US$ Million), 2017 - 2019

Figure 16-12: Europe - Faslodex Annual Sales Value (US$ Million), 2017 - 2019

Figure 16-13: Global - Faslodex Annual Sales Value by Region (US$ Million), 2019

Figure 16-14: Global - Faslodex Annual Sales Value by Region (%), 2019

Figure 16-15: Global - Faslodex Quarterly Sales Value (US$ Million), Q1 – Q3, 2020

Figure 16-16: Global - Faslodex 9 Month Sales Value by Region (US$ Million), 2020

Figure 16-17: Global - Faslodex 9 Month Sales Value by Region (%), 2019

Figure 16-18: US - Faslodex Quarterly Sales Value (US$ Million), Q1 – Q3, 2020

Figure 16-19: Europe - Faslodex Quarterly Sales Value (US$ Million), Q1 – Q3, 2020

Figure 17-1: Cyclophosphamide – Price for various Supplies of intravenous Powder for Injection (US$), January’2021

Figure 17-2: Cyclophosphamide – Price for various Supplies of 200mg/ml intravenous Solution for Injection (US$), January’2021

Figure 17-3: Cyclophosphamide – Price for 100 Capsule Supply of 25mg and 50mg Dose (US$), January’2021

Figure 17-4: Cyclophosphamide – Minimum and Maximum Dose as Single Agent (mg/Kg), January’2021

Figure 17-5: Thiotepa – Price for the Supply of 15 mg and 100mg Injectable Powder for Injection (US$), January’2021

Figure 17-6: Tipadina – Price for the Supply of 15 mg and 100mg Injectable Powder for Injection (US$), January’2021

Figure 177: Tipadina – Minimum and Maximum Dose per Cycle (mg/Kg/Cycle), January’2021

Figure 17-8: Tipadina – Minimum and Maximum Duration of Single Treatment Cycle (Week), January’2021

Figure 18 -1: Tukysa – Patent Issue and Expiration Year

Figure 18-2: Tukysa – Price for the Supply of 60 Tablets and Price per Unit Tablet of 50mg (US$), January’2021

Figure 18-3: Tukysa – Price for the Supply of 60 Tablets and Price per Unit Tablet of 50mg (US$), January’2021

Figure 18-4: Tukysa – Recommended Initial and Reduced Dose (mg twice daily), January’2021

Figure 18-5: Aridamycin – Price for various Supplies of Intravenous Powder for Injection (US$), January’2021

Figure 18-6: Aridamycin – Price for Various Supplies of intravenous Solution for Injection (US$), January’2021

Figure 18-7: Generic Doxorubicin – Price for Various Supplies of intravenous Solution for Injection (US$), January’2021

Figure 18-8: Aridamycin – Recommended Minimum and Maximum Dose as Single Agent (mg/m2/Cycle), January’2021

Figure 18-9: Aridamycin – Duration of Single Treatment Cycle and Full Treatment as Combinational Agent (Weeks), January’2021

Figure 18-10: Everolimus – FDA Approval Year and First Generic Approval Year

Figure 18-11: Everolimus - Patent Issue and Expiration Year

Figure 18-12: Afinitor – Price for 28 Tablets Supply and Price per unit Tablet of 2.5 mg (US$), January’2021

Figure 18-13: Afinitor – Price for 28 Tablets Supply and Price per unit Tablet of 5mg, 7.5mg and 10mg Dose (US$), January’2021

Figure 18-14: Everolimus – Price for 28 Tablets Supply and Price per unit Tablet of 2.5 mg (US$), January’2021

Figure 18-15: Everolimus – Price for 28 Tablets Supply and Price per unit Tablet of 5mg and 7.5mg Dose (US$), January’2021

Figure 18-16: Afinitor – Recommended Initial and Reduced Dose (mg/day)

Figure 18-17: Piqray - Patent Issue and Expiration Year

Figure 18-18: Piqray – Price for Supply of 56 Tablets and Price per unit Tablet of 200-50mg and 150mg (US$), January’2021

Figure 18-19: Piqray – Price for Supply of 28 Tablets and Price per unit Tablet of 200mg (US$), January’2021

Figure 18-20: Piqray – Recommended and Reduced Dose (mg/day), January’2021

Figure 21-1: Number of 65+ years Americans (in Million), 1960 till 2040

Figure 21-2: Breast Cancer – Average Cost (US$ '000) by Disease Stage at Diagnosis